Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Malaria Drug Artesunate Activates Lysosomal Cell Death in Cancer Cells

No. 36a | 11/07/2011

Heidelberg scientists have investigated cellular processes in killing breast cancer cells.

In cancer cells treated with arsenuate, mitochondria (green) as well as lysosomae (red) appear fragmented, accummulated around the nuclei. Untreated cancer cells, in contrast, appear to have a network of mitochondria and lysosomae distributed evenly over the entire cell.

Artemisinin – a substance obtained from a medicinal plant used for the treatment of malaria may potentially be used also for cancer treatment. Scientists of BioQuant Center of Heidelberg University and the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have investigated cellular processes in killing breast cancer cells using artesunate, an artemisinin derivative. They were able to show that membrane-bound cell organelles known as lysosomes and reactive iron contained therein play a key role in artesunate-induced cell death of cancer cells. Their research results were published in the Journal of Biological Chemistry.

Extracts of the medicinal plant Artemisia annua (annual wormwood) have been used in traditional Chinese medicine for over two thousand years. In the 1970s, the active substance artemisinin was identified and clinically characterized as an effective antimalarial agent. Today, artemisinins are used worldwide for malaria treatment. One of its derivatives is artesunate, which like artemisinin unfolds its cytotoxic effect through chemical reaction with iron. In the process, reactive oxygen species, commonly known as free oxygen radicals, are produced. In malaria parasites, the cytotoxicity of artemisinin originates from the food vacuole, which contains high levels of redox-active iron formed as a result of the breakdown of host hemoglobin.

Analogous to the food vacuoles of the malaria parasite, the Heidelberg group studied the role of lysosomes in artesunate-induced programmed cell death in breast cancer cells. Lysosomes are membrane-bound eukaryotic cell organelles which use specific enzymes to break down cellular components. In addition, like the food vacuole of malaria parasites, they contain high levels of redox-active iron. This lysosomal iron was identified by the investigators as the key starting point of cell death induced by artesunate in breast cancer cells. The research group “Systems Biology of Cell Death Mechanisms” headed by Dr. Nathan Brady found out that blockage of reactive iron in the lysosomes protects cancer cells, while, on the other hand, an increase of lysosomal iron levels enhances the cytotoxic effect of artesunate on cancer cells.

Dr. Anne Hamacher-Brady, scientist in the research group “Integrative Bioinformatics and Systems Biology“ headed by Prof. Dr. Roland Eils explains that intact lysosomes are required for the cell death signal to be passed on to the mitochondria. Mitochondria, normally known as the powerhouses of the cell, frequently play a role in programmed cell death, or apoptosis, by releasing what are called pro-apoptotic molecules. In artesunate-induced cell death, this transformation of mitochondria into killer organelles happens depending on lysosomal iron. The scientists were also able to show that artesunate, through its influence on the spatial distribution of cellular components, blocks particular processes which normally support survival and spread of cancer cells. This includes, among others, the process of autophagy in which a cell uses its lysosomal machinery to break down own components in order to recycle vital macromolecules in situations of restricted nutrient supply such as inside a tumor.

As the Heidelberg researchers report, cell death through artesunate was triggered only in breast cancer cells, not in “healthy” mammary epithelial cell lines. Their hypothesis is that this selectivity for cancer cells may be caused by the fact that cancer cells have an increased need of iron due to changes in their metabolism. This is the subject of ongoing studies conducted by the two research groups at BioQuant Center. More information is available on the Internet at under the keyword “Artesunate“.

Original publication:
A. Hamacher-Brady, H.A. Stein, S. Turschner, I. Toegel, R. Mora, N. Jennewein, T. Efferth, R. Eils, N.R. Brady: Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalysed lysosomal reactive oxygen species production. J Biol Chem. 2011 Feb 25; 286(8): 6587-6601, DOI: 10.1074/jbc.M110.210047.

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. More than 1,300 scientists at the DKFZ investigate how cancer develops, identify cancer risk factors and search for new strategies to prevent people from developing cancer. They are developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to all questions on cancer.

Jointly with partners from the university hospitals, the DKFZ operates the National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children's Cancer Center KiTZ in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. NCT and DKTK sites combine excellent university medicine with the high-profile research of the DKFZ. They contribute to the endeavor of transferring promising approaches from cancer research to the clinic and thus improving the chances of cancer patients.

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS